// App-Quantinova.ai

Sa1214 : Rates of Patient-Defined Remission With Adalimumab in Patients With Ulcerative Colitis: Subanalysis of ULTRA 1 and ULTRA 2

Researchers

Presenter

  • James D. Lewis

Principal Investigators

  • Subrata Ghosh

  • William J Sandborn

  • Gert A. Van Assche

  • Geert R. D'Haens

  • Andreas Lazar

  • Samantha Eichner

  • Bidan Huang

  • Anne M Robinson

  • Roopal Thakkar

Medical Centers

  • Imelda GI Clinical Research Center, Bonheiden, Belgium

  • University of California, San Diego, La Jolla, CA

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

  • University of Toronto, Toronto, ON, Canada

  • University of Leuven, KUL, Leuven, Belgium

  • University of Calgary, Calgary, AB, Canada

  • Academic Medical Center, Amsterdam, Netherlands

Locations

  • United States

  • Canada

  • Belgium

  • Netherlands

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved